Search

Displaying results 4041 - 4050 of 8412 in total
  1. Drug

    Zopiclone

    go.drugbank.com/drugs/DB01198
    ApprovedInvestigational

    Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbitu...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesProducts: Mar-zopiclone, Ag-zopiclone
  2. Drug

    AGRO100

    go.drugbank.com/drugs/DB04998
    Investigational

    AGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells.

  3. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    N-acetyltyrosine is administered as parenteral nutrition or intravenous infusion due to its enhanced solubility compared to tyrosine [A32652].

  4. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.

  5. Drug

    Nevadistinel

    go.drugbank.com/drugs/DB21632
    Investigational

    Nevadistinel has a monoisotopic molecular weight of 274.13 Da. … The usage of the INN stem '-stinel' in the name indicates that Nevadistinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist.

  6. Drug

    BRD-810

    go.drugbank.com/drugs/DB23607
    Experimental

    BRD-810 is an experimental small molecule being investigated as a potential anti-cancer medication. It is an inhibitor of the protein myeloid cell leukemia 1 (MCL1). [A274263]

  7. Drug

    Rebastinib

    go.drugbank.com/drugs/DB13005
    Investigational

    It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.

  8. Drug

    Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen

    go.drugbank.com/drugs/DB16902
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16903
    ApprovedWithdrawn

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16910
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen